Metropolis Healthcare Ltd
Metropolis Healthcare Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Revenue Growth Guidance: Metropolis Healthcare expects a CAGR of 14% to 15% in revenue over the next 3 years. Metropolis Healthcare projects a revenue CAGR of 14% to 15% over the next 3 years driven by patient volume growth, realization improvement, and strategic acquisitions.
From Metropolis Healthcare Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Revenue Growth Guidance: Metropolis Healthcare expects a CAGR of 14% to 15% in revenue over the next 3 years.
- Volume Growth: Patient volume growth is forecasted at about 8% to 9% for the coming fiscal, contributing significantly to overall growth.
- Realization/Price Growth: Approximately 5% of growth is expected from better price realization driven by specialty and core diagnostics.
- Digital Channels: Digital revenue has grown to 25% and is expected to further drive volume and margin expansion.
- Network Expansion: Focus on enhancing productivity of existing centers by 20% over 3 years and adding 1,500 new collection centers to improve the lab-to-center ratio from 1:24 to 1:35.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Metropolis Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY26 capex stood at INR 65 crores, focused on targeted network addition, specialty test expansion, technology upgrades, and digital capabilities.
- Future investments will be increasingly selective and productivity-driven.
- Plan to build around 100 mini hubs over the next 3 years, combining pathology and basic radiology services for retail and corporate clients.
- Mini hubs capex estimated at INR 30-40 lakhs each, higher than collection centers but similar to satellite labs.
- Expansion of the asset-light collection center network by adding 1,500 more centers, improving the lab-to-center ratio from 1:24 to 1:35.
- Emphasis on technology enablement and automation to drive center productivity and margin expansion.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Metropolis Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Metropolis Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹425 Cr, net profit ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Metropolis Healt's management said in earlier quarters
Others in Healthcare Services this season
- KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
- Gaudium IVF (Q4 FY26)
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25. Key concall takeaways from Gaudium IVF's Q4 FY26 earnings call — and how it ranks…
- Apollo Hospitals Enterprise Ltd (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…
Frequently Asked Questions
What were Metropolis Healthcare Ltd Q4 FY26 results?
Revenue Growth Guidance: Metropolis Healthcare expects a CAGR of 14% to 15% in revenue over the next 3 years. Metropolis Healthcare projects a revenue CAGR of 14% to 15% over the next 3 years driven by patient volume growth, realization improvement, and strategic acquisitions.
What is Metropolis Healthcare Ltd share price analysis?
Metropolis Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 54.4 with a market cap of ₹11,313 Cr. Investors should review the full earnings analysis for detailed insights.
Is Metropolis Healthcare Ltd planning capital expenditure?
FY26 capex stood at INR 65 crores, focused on targeted network addition, specialty test expansion, technology upgrades, and digital capabilities.
Keep Metropolis Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.